Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

In a report released yesterday, from Shore Capital reiterated a Buy rating on Origin Enterprises plc. The company’s shares closed yesterday at €4.4...

Shore Capital Reaffirms Their Buy Rating on Origin Enterprises plc (OGN)

New activity is brewing for Organon ( ($OGN) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This ...

Organon Sets July Vote on $14‑per‑Share Sun Pharma Takeover

Organon ( ($OGN) ) has provided an announcement. At its 2026 annual meeting held on June 9, 2026, Organon stockholders elected ten board nominees t...

Market Cap	$2.38B	P/E Ratio	4.17
52W High	$13.49	52W Low	$5.69
Div Yield	8.0%	Payout Ratio	9.0%
EPS Growth 3Y	-41.6%	52W Position	99.9%
Overall Score	70	Value Score	100
Quality Score	36	Technical Score	75

EPS Current Est	$3.23	EPS Next Est	$3.44
EPS Growth Est	+6.5%	DPS Growth 3Y	-32.8%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$13.48	+0.22%	2.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$13.48	+0.2%	2.99M
3
4
5
6

OGN

OGN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel